Trial reportDrug design, development and therapy2025
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of QP002 for the Treatment of Post-Operative Pain After Tension-Free Repair of Open Unilateral Inguinal Hernia.
Trial report in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: QP002 Long-acting local anaesthetic with bupivacaine and low-dose meloxicam as active ingredients for postoperative regional analgesia. The objective of the present study was to evaluate the safety, tolerability, and pharmacokinetics (PK) and pharmacodynamics (PD) of QP002 for postoperative analgesia following tension-free repair of an open unilateral inguinal hernia. Methods: This was a multicentre, randomised, double-blind, positive-controlled trial. Patients were randomly assigned to receive a single injection of QP002 (five dose groups) with 0.25% bupivacaine hydrochloride 75 mg after open unilateral tension-free repair of an inguinal hernia. Pharmacokinetic parameters were evaluated by obtaining pharmacokinetic characteristic blood samples before and 120 hours after administration, at a total of 20 sampling points. Adverse events occurring after treatment were recorded from baseline to postoperative day 27 follow-up. Results: A total of 40 patients with unilateral inguinal hernia were included in this study. In comparison to 0.25% bupivacaine hydrochloride 75 mg, the results demonstrate that QP002 was well tolerated, with no additional adverse events (AEs) observed and no instances of serious adverse events (SAEs). QP002 demonstrated prolonged absorption and clearance of bupivacaine, including a longer time to reach peak plasma concentration and a terminal elimination half-life. The peak plasma concentrations of 240 mg/7.2 mg QP002 (C Conclusion: QP002 demonstrated favorable safety profiles and exhibited distinct extended-release pharmacokinetic (PK) characteristics in single-ascending-dose administration. High doses of QP002 showed potential for postoperative incisional infiltration to control pain. Future studies will further explore its efficacy and safety in broader clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.